Cargando…
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
BACKGROUND: We and others have recently shown that tumor characteristics are altered throughout tumor progression. These findings emphasize the need for re-examination of tumor characteristics at relapse and have led to recommendations from ESMO and the Swedish Breast Cancer group. Here, we aim to d...
Autores principales: | Tobin, N. P., Harrell, J. C., Lövrot, J., Egyhazi Brage, S., Frostvik Stolt, M., Carlsson, L., Einbeigi, Z., Linderholm, B., Loman, N., Malmberg, M., Walz, T., Fernö, M., Perou, C. M., Bergh, J., Hatschek, T., Lindström, L. S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269343/ https://www.ncbi.nlm.nih.gov/pubmed/25361981 http://dx.doi.org/10.1093/annonc/mdu498 |
Ejemplares similares
-
Immune gene expression and response to chemotherapy in advanced breast cancer
por: Foukakis, Theodoros, et al.
Publicado: (2018) -
Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications
por: Kimbung, Siker, et al.
Publicado: (2015) -
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance
por: Azimi, A, et al.
Publicado: (2014) -
Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma
por: Falkenius, Johan, et al.
Publicado: (2017) -
Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
por: Einbeigi, Z., et al.
Publicado: (2008)